Trial Profile

Phase II Study of Evaluating Efficacy, Safety and Tolerance of KN026 in HER2 Expressing Advanced Gastric/Gastroesophageal Junction Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anbenitamab (Primary)
Indications Carcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Sponsors Jiangsu Alphamab Biopharmaceuticals

Most Recent Events

11 Mar 2024 Status changed from recruiting to completed.
19 Oct 2022 Results(n=45) assessing safety and efficacy results of the phase 2 trial in patients with advanced HER2-expressing gastric or gastroesophageal junction cancer published in the European Journal of Cancer
07 Jun 2022 Results (n=45; data cutoff date: 29 Oct 2021) reporting efficacy and safety data presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com